Kura Oncology Inc (KURA)
10.80
+0.74
(+7.36%)
USD |
NASDAQ |
Nov 22, 16:00
10.80
0.00 (0.00%)
After-Hours: 20:00
Kura Oncology Cash from Investing (Quarterly): 45.54M for Sept. 30, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 45.54M |
| June 30, 2024 | 43.17M |
| March 31, 2024 | -95.34M |
| December 31, 2023 | 42.20M |
| September 30, 2023 | 8.559M |
| June 30, 2023 | -46.33M |
| March 31, 2023 | 11.13M |
| December 31, 2022 | -47.32M |
| September 30, 2022 | 71.81M |
| June 30, 2022 | 33.10M |
| March 31, 2022 | -24.96M |
| December 31, 2021 | 74.06M |
| September 30, 2021 | 22.54M |
| June 30, 2021 | -37.22M |
| March 31, 2021 | -186.22M |
| December 31, 2020 | -60.19M |
| September 30, 2020 | -45.52M |
| June 30, 2020 | -21.69M |
| March 31, 2020 | 27.46M |
| December 31, 2019 | -15.26M |
| Date | Value |
|---|---|
| September 30, 2019 | -55.75M |
| June 30, 2019 | 8.876M |
| March 31, 2019 | 15.81M |
| December 31, 2018 | 4.618M |
| September 30, 2018 | -58.06M |
| June 30, 2018 | 3.857M |
| March 31, 2018 | -29.71M |
| December 31, 2017 | -4.091M |
| September 30, 2017 | -36.29M |
| June 30, 2017 | 7.433M |
| March 31, 2017 | 9.534M |
| December 31, 2016 | 9.68M |
| September 30, 2016 | 0.143M |
| June 30, 2016 | -5.842M |
| March 31, 2016 | 8.197M |
| December 31, 2015 | -40.45M |
| September 30, 2015 | -3.891M |
| June 30, 2015 | -26.28M |
| March 31, 2015 | -0.01M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-186.22M
Minimum
Mar 2021
74.06M
Maximum
Dec 2021
-10.02M
Average
-3.349M
Median
Cash from Investing (Quarterly) Benchmarks
| Halozyme Therapeutics Inc | -167.48M |
| AIM ImmunoTech Inc | 0.334M |
| Perspective Therapeutics Inc | -29.74M |
| Protalix BioTherapeutics Inc | 20.33M |
| Armata Pharmaceuticals Inc | -0.34M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -43.44M |
| Cash from Financing (Quarterly) | 2.202M |
| Free Cash Flow | -169.24M |
| Free Cash Flow Per Share (Quarterly) | -0.4996 |
| Free Cash Flow Yield | -18.72% |